Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $31.29

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $29.50.

RCUS has been the topic of a number of recent analyst reports. Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday. Bank of America lowered their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, HC Wainwright decreased their price objective on shares of Arcus Biosciences from $20.00 to $18.00 and set a "neutral" rating on the stock in a report on Tuesday.

Arcus Biosciences Trading Up 3.0 %

NYSE:RCUS traded up $0.32 on Tuesday, hitting $11.06. The stock had a trading volume of 1,238,479 shares, compared to its average volume of 894,829. The company has a fifty day moving average price of $13.92 and a two-hundred day moving average price of $15.55. Arcus Biosciences has a 1-year low of $10.63 and a 1-year high of $20.31. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -3.51 and a beta of 0.84.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company's stock, valued at $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcus Biosciences

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after purchasing an additional 833 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcus Biosciences by 2.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company's stock worth $471,000 after purchasing an additional 843 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Arcus Biosciences by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after buying an additional 1,117 shares during the last quarter. R Squared Ltd acquired a new stake in Arcus Biosciences in the fourth quarter valued at $26,000. Finally, Teacher Retirement System of Texas raised its stake in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after buying an additional 2,410 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.